{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:19:23Z","timestamp":1772129963564,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T00:00:00Z","timestamp":1286150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region\u2010Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long\u2010term imatinib therapy; however, the availability of the second\u2010generation TKIs nilotinib and dasatinib limits the need for patients intolerant to imatinib to continue with therapy. Unfortunately, there is currently no standard definition of intolerance to imatinib. Common Toxicity Criteria for grading adverse events, designed to identify acute toxicities, are often used to determine intolerance. However, because CML therapies are long\u2010term, patient quality of life may provide a better measure of true intolerance. Several general methods of quantifying patient quality of life are in use for patients with CML, and a CML\u2010specific variant of the M. D. Anderson Symptom Inventory is in development. An appropriate and consistent definition of intolerance will provide clinicians with an algorithm for managing their patients with severe or chronic adverse events during treatment with imatinib. As more long\u2010term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.25648","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T17:16:08Z","timestamp":1286212568000},"page":"688-697","source":"Crossref","is-referenced-by-count":53,"title":["Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia"],"prefix":"10.1002","volume":"117","author":[{"given":"Javier","family":"Pinilla\u2010Ibarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,4]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_10_6_2","volume-title":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2","year":"2010"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903479299"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.4065\/82.10.1229"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:QURE.0000015297.91158.01"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.154"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_10_14_2","first-page":"2897","article-title":"Common toxicity criteria versus symptom specific measures: how congruent are the data?","volume":"21","author":"Varricchio CG","year":"2002","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp386"},{"key":"e_1_2_10_16_2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood.V112.11.2408.2408","article-title":"The symptom burden of chronic myelogenous leukemia (CML)","volume":"112","author":"Williams LA","year":"2008","journal-title":"Blood."},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00061-7"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_10_19_2","first-page":"464","article-title":"Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: clinical response, safety, and long\u2010term outcomes","volume":"114","author":"Kantarjian HM","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_20_2","first-page":"457","article-title":"Patterns and management of selected adverse events of adult patients with imatinib\u2010resistant or \u2010intolerant chronic myeloid leukemia (CML) from the ENACT (expanding nilotinib access in clinical trials) study","volume":"114","author":"le Coutre PD","year":"2009","journal-title":"Blood."},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_10_22_2","volume-title":"Gleevec (imatinib) [package insert]","year":"2008"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_10_26_2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.V114.22.3294.3294","article-title":"Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph\u2010positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 phase 2 study","volume":"114","author":"O'Dwyer MC","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_10_29_2","doi-asserted-by":"crossref","first-page":"387s","DOI":"10.1200\/jco.2008.26.15_suppl.7063","article-title":"Minimal cross\u2010intolerance between nilotinib and imatinib in patients with imatinib\u2010intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)","volume":"26","author":"Jabbour E","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_30_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.V114.22.2201.2201","article-title":"Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib\u2010resistant or \u2010intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub\u2010analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study","volume":"114","author":"Nicolini FE","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070144"},{"key":"e_1_2_10_33_2","doi-asserted-by":"crossref","first-page":"375s","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia chronic phase (CML\u2010CP) intolerant to imatinib: a retrospective analysis of safety","volume":"26","author":"Khoury HJ","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24432"},{"key":"e_1_2_10_37_2","volume-title":"Sprycel (dasatinib) [package insert]","year":"2009"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180604"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25648","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:33:41Z","timestamp":1760294021000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25648"}},"subtitle":["Definitions and clinical implications"],"short-title":[],"issued":{"date-parts":[[2010,10,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,2,15]]}},"alternative-id":["10.1002\/cncr.25648"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25648","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,4]]}}}